ArriVent Biopharma

👥 44 employees💰 Last funded Mar 2023
Biotechnology Research🌐 arrivent.com
Website LinkedIn
ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Hong Kong SAR
2
Frequently asked questions
Who invested in ArriVent Biopharma?
ArriVent Biopharma has 2 investors on record on gritt.io.
When did ArriVent Biopharma last raise funding?
The most recent investment in ArriVent Biopharma recorded on gritt.io was in March 2023.
What industry is ArriVent Biopharma in?
ArriVent Biopharma operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.